Immunogenic tumor cell death promotes dendritic cell migration and inhibits tumor growth via enhanced T cell immunity

被引:26
作者
Moriya, Taiki [1 ]
Kitagawa, Kurumi [1 ]
Hayakawa, Yuuki [1 ]
Hemmi, Hiroaki [2 ]
Kaisho, Tsuneyasu [2 ]
Ueha, Satoshi [3 ]
Ikebuchi, Ryoyo [1 ,4 ]
Yasuda, Ippei [1 ]
Nakanishi, Yasutaka [1 ]
Honda, Tetsuya [5 ]
Matsushima, Koji [3 ]
Kabashima, Kenji [5 ]
Ueda, Mizuki [1 ]
Kusumoto, Yutaka [1 ]
Chtanova, Tatyana [6 ,7 ]
Tomura, Michio [1 ]
机构
[1] Osaka Ohtani Univ, Fac Pharm, Lab Immunol, Tondabayashi, Osaka 5848540, Japan
[2] Wakayama Med Univ, Grad Sch Med, Inst Adv Med, Dept Immunol, Wakayama 6418509, Japan
[3] Tokyo Univ Sci, Res Inst Biomed Sci, Div Mol Regulat Inflammatory & Immune Dis, Noda, Chiba 2780022, Japan
[4] Res Fellow Japan Soc Promot Sci, Tokyo, Japan
[5] Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyou Ku, Kyoto 6068507, Japan
[6] Garvan Inst Med Res, Immunol Theme, Darlinghurst, NSW 2010, Australia
[7] Univ New South Wales Sydney, Fac Sci, Sch Biotechnol & Biomol Sci, Kensington, NSW 2033, Australia
基金
英国医学研究理事会;
关键词
ANTICANCER CHEMOTHERAPY; RECEPTOR; CANCER; IMMUNOTHERAPY; LYMPHOCYTES; EXPOSURE; ANTIGENS; PROTEIN; INDUCE;
D O I
10.1016/j.isci.2021.102424
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Immunogenic tumor cell death enhances anti-tumor immunity. However, the mechanisms underlying this effect are incompletely understood. We established a system to induce tumor cell death in situ and investigated its effect on dendritic cell (DC) migration and T cell responses using intravital photolabeling in mice expressing KikGR photoconvertible protein. We demonstrate that tumor cell death induces phagocytosis of tumor cells by tumor-infiltrating (Ti)-DCs, and HMGB1-TLR4 and ATP-P2X7 receptor signaling-dependent Ti-DC emigration to draining lymph nodes (dLNs). This led to an increase in anti-tumor CD8(+) T cells of memory precursor effector phenotype and secondary tumor growth inhibition in a CD103(+) DC-dependent manner. However, combining tumor cell death induction with lipopolysaccharide treatment stimulated Ti-DC maturation and emigration to dLNs but did not improve tumor immunity. Thus, immunogenic tumor cell death enhances tumor immunity by increasing Ti-DC migration to dLNs where they promote anti-tumor T cell responses and tumor growth inhibition.
引用
收藏
页数:35
相关论文
共 53 条
  • [1] Abbas AK, 2015, CELL MOL IMMUNOL
  • [2] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
    Apetoh, Lionel
    Ghiringhelli, Francois
    Tesniere, Antoine
    Obeid, Michel
    Ortiz, Carla
    Criollo, Alfredo
    Mignot, Gregoire
    Maiuri, M. Chiara
    Ullrich, Evelyn
    Saulnier, Patrick
    Yang, Huan
    Amigorena, Sebastian
    Ryffel, Bernard
    Barrat, Franck J.
    Saftig, Paul
    Levi, Francis
    Lidereau, Rosette
    Nogues, Catherine
    Mira, Jean-Paul
    Chompret, Agnes
    Joulin, Virginie
    Clavel-Chapelon, Francoise
    Bourhis, Jean
    Andre, Fabrice
    Delaloge, Suzette
    Tursz, Thomas
    Kroemer, Guido
    Zitvogel, Laurence
    [J]. NATURE MEDICINE, 2007, 13 (09) : 1050 - 1059
  • [3] CD169-Positive Macrophages Dominate Antitumor Immunity by Crosspresenting Dead Cell-Associated Antigens
    Asano, Kenichi
    Nabeyama, Ami
    Miyake, Yasunobu
    Qiu, Chun-Hong
    Kurita, Ai
    Tomura, Michio
    Kanagawa, Osami
    Fujii, Shin-ichiro
    Tanaka, Masato
    [J]. IMMUNITY, 2011, 34 (01) : 85 - 95
  • [4] The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
    Boettcher, Jan P.
    Reis e Sousa, Caetano
    [J]. TRENDS IN CANCER, 2018, 4 (11): : 784 - 792
  • [5] A nanoparticle-based approach to improve the outcome of cancer active immunotherapy with lipopolysaccharides
    Boushehri, Maryam A. Shetab
    Abdel-Mottaleb, Mona M. A.
    Beduneau, Arnaud
    Pellequer, Yann
    Lamprecht, Alf
    [J]. DRUG DELIVERY, 2018, 25 (01) : 1414 - 1425
  • [6] Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity
    Broz, Miranda L.
    Binnewies, Mikhail
    Boldajipour, Bijan
    Nelson, Amanda E.
    Pollack, Joshua L.
    Erle, David J.
    Barczak, Andrea
    Rosenblum, Michael D.
    Daud, Adil
    Barber, Diane L.
    Amigorena, Sebastian
    van't Veer, Laura J.
    Sperling, Anne I.
    Wolf, Denise M.
    Krummel, Matthew F.
    [J]. CANCER CELL, 2014, 26 (05) : 638 - 652
  • [7] Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
    Casares, N
    Pequignot, MO
    Tesniere, A
    Ghiringhelli, F
    Roux, S
    Chaput, N
    Schmitt, E
    Hamai, A
    Hervas-Stubbs, S
    Obeid, M
    Coutant, F
    Métivier, D
    Pichard, E
    Aucouturier, P
    Pierron, G
    Garrido, C
    Zitvogel, L
    Kroemer, G
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (12) : 1691 - 1701
  • [8] Monocyte-derived DC maturation strategies and related pathways: a transcriptional view
    Castiello, Luciano
    Sabatino, Marianna
    Jin, Ping
    Clayberger, Carol
    Marincola, Francesco M.
    Krensky, Alan M.
    Stroncek, David F.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (04) : 457 - 466
  • [9] The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment
    De Marchi, Elena
    Orioli, Elisa
    Pegoraro, Anna
    Sangaletti, Sabina
    Portararo, Paola
    Curti, Antonio
    Colombo, Mario Paolo
    Di Virgilio, Francesco
    Adinolfi, Elena
    [J]. ONCOGENE, 2019, 38 (19) : 3636 - 3650
  • [10] Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
    Durgeau, Aurelie
    Virk, Yasemin
    Corgnac, Stephanie
    Mami-Chouaib, Fathia
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9